peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Medical’s annual report of 2011 (in Swedish) has been published

23 Apr 2012, 15:15
Regulatory information
The Hansa Medical Annual Report of 2011 has been published at the corporate website www.hansamedical.com

A print version of the annual report in Swedish can be ordered at Hansa Medical AB, Investor Relations, P.O. Box 785, 220 07 Lund, Sweden, via fax +46 46-12 77 75 or through e-mail at info@hansamedical.com.

Files

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com

Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoSand HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company’s Certified Adviser.